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Abstract The Endocrine Tumor Summit convened in
December 2008 to address 6 statements prepared by panel
members that reﬂect important questions in the treatment of
acromegaly and carcinoid syndrome. Data pertinent to each
ofthe statementswere identiﬁedthrough review ofpertinent
literature by one of the 9-member panel, enabling a critical
evaluation of the statements and the evidence supporting
or refuting them. Three statements addressed the validity
of serum growth hormone (GH) and insulin-like growth
factor-I (IGF-I) concentrations as indicators or predictors of
disease in acromegaly. Statements regarding the effects of
preoperative somatostatin analog use on pituitary surgical
outcomes, their effects on hormone and symptom control in
carcinoid syndrome, and the efﬁcacy of extended dosing
intervals were reviewed. Panel opinions, based on the level
of available scientiﬁc evidence, were polled. Finally, their
views were compared with those of surveyed community-
based endocrinologists and neurosurgeons.
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Introduction
Despite considerable progress in deﬁning criteria for dis-
ease control in patients with acromegaly, a number of
controversies exist regarding the use of GH and IGF-I
measurements towards this end. Similarly, the use of
somatostatin analogs in the treatment of acromegaly has
strikingly altered disease outcomes for patients with this
disease, as well as symptom control for patients with neu-
roendocrine tumors (NETs). However, issues of use of these
medications preoperatively in patients with acromegaly,
dosing intervals, and treatment efﬁcacy remain. In the
Summit proceedings summarized, an expert panel was
asked to examine a number of controversial statements
pertaining to current therapeutic approaches in the man-
agement of acromegaly and carcinoid syndrome (Table 1).
Evidence both supporting and contradicting the statement
was presented, and panelists were asked to decide, based on
the evidence in the literature, on their degree of acceptance
of each statement. The results from the Summit voting were
compared with the ﬁndings of an electronic survey con-
taining the same statements as voted on by the workshop
panel. The 100 respondents consisted of endocrinologists
and neurosurgeons, all of whom treat patients with either
acromegaly or neuroendocrine and/or pituitary tumors.
Survey respondents have practiced from 1 to 10 years and
represented various geographic regions of the United States.
Statement 1: an IGF-I value that is normal for age
and gender signiﬁes control of acromegaly
Rationale and deﬁnition of statement
Although serum IGF-I levels offer value in monitoring
control of acromegaly, their precise role is still developing.
The increasing body of data in this relatively small popu-
lation warrants a new critical look, comparing it with
biochemical markers such as GH as well as other endpoints
used to assess acromegaly control, including mortality,
morbidity, symptom control, and quality of life (QOL).
Literature search
A literature search was undertaken in October 2008 using
the search terms ‘‘serum IGF-I,’’ ‘‘serum somatomedin C,’’
and ‘‘diabetes,’’ each combined with ‘‘acromegaly.’’ 1121
titles were reviewed; 130 abstracts were selected for further
review. Of these, 47 publications that appeared to be rel-
evant were examined more comprehensively, resulting in
15 that were directly relevant to the statement.
Evidence
One of the principal indices of remission in acromegaly has
been the GH response to oral glucose tolerance testing
(OGTT). To determine whether there was a relationship
between the response of glucose-suppressed GH and serum
IGF-I, Vierhapper et al. [1] analyzed 26 untreated acro-
megalic patients and 71 patients post transsphenoidal sur-
gery. OGTT with GH sampling and IGF-I were measured
in all subjects. IGF-I was found to vary with age and
Table 1 Clinical practice statements
Statements 1–6
1. An IGF-I value that is normal for age and gender signiﬁes control of acromegaly
2. A GH of B1.0 lg/l as a random measurement or as a nadir after an oral glucose tolerance test correlates with disease control in patients with
acromegaly
3. GH levels sampled at any time interval are better predictors of control of acromegaly and related morbidity than IGF-I levels
4. The administration of somatostatin analogs prior to transsphenoidal surgery improves surgical outcome and disease morbidity associated with
acromegaly
5. The dosing interval of a somatostatin analog can be extended beyond once every 4 weeks without compromising disease control in patients
with acromegaly
6. A monthly injection of the depot form of lanreotide or octreotide results in consistent control of hormone levels and symptoms in patients with
carcinoid syndrome
IGF-I insulin-like growth factor-I, GH growth hormone
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123gender, and GH suppression varied with age and BMI. Post
surgery, IGF-I response and normalization of glucose-
suppressed GH were congruent in 77% of the patients. The
authors demonstrated that across the board cutoff values
for either parameter could not be applied to the entire
population. They concluded that post-treatment OGTT GH
and IGF-I responses should be interpreted individually.
One problem in attempting to correlate IGF-I values and
GH suppression following treatment of acromegaly has
been to establish cutoff values for GH suppression. Over
the years, this cutoff value has varied from 5 ng/ml to the
current recommendation of less than 2.5 ng/ml by con-
ventional radioimmunoassay or less than 1 ng/ml by sen-
sitive chemiluminescence assay. The natural history and
ultimate outcome of patients with values between 0.3 and
1 ng/ml has not been widely studied in detail.
Ronchi et al. [2] studied 40 subjects followed for
14.3 years ± 4.2 (mean ± SD) after transsphenoidal sur-
gery. The authors stratiﬁed patients into two levels of
GH suppression: GH\0.19 ng/ml (deﬁning a cure) or
GH\0.77 ng/ml (deﬁning a major improvement). No
difference in clinical outcome was noted between those
groups. All subjects in both groups had a normal IGF-I;
only 2% of patients with normal IGF-I levels had tumor
recurrence. Ronchi et al. concluded that although minor
abnormalities of GH suppression might persist in some
patients, normalization of IGF-I levels generally indicated
an excellent prognosis.
Other observational studies compared the frequency of
normal IGF-I values to suppressed GH in patients with
acromegaly. Nomikos et al. [3] studied 506 out of 688
patients who had been treated surgically. Cures occurred
in 57.3% of patients, as deﬁned by a basal GH less than
2.5 ng/ml (or a response to oral glucose less than 1 ng/ml).
Importantly, in this large series, the percentage of subjects
who had a normal post OGTT GH value and an IGF-I in the
normalrangeweresimilar.Therefore,theauthorsconcluded
there were not signiﬁcant differences between measuring
one parameter or the other in terms of deﬁning cure.
Another study compared the response to conventional
radiation therapy. Jenkins et al. [4] studied 1080 subjects,
856 of whom had received conventional RT. After
10 years, 60% of patients had a GH value less than 2 ng/ml
and 63% had a normal IGF-I level. Although the number of
discrepancies was not reported, it is signiﬁcant that the
same percentage had this degree of improvement in both
parameters, suggesting that there was a high level of con-
cordance between the two measurements.
A few studies have examined the degree of improvement
inGHandIGF-Ilevelsaftersurgery,studyingthecorrelation
of biochemical responses with improvement in signs or
symptoms of disease activity. Clemmons et al. [5] demon-
strated that IGF-I at diagnosis corresponded with soft tissue
enlargement (r = 0.77), as well as with the degree of
abnormalityinfastingbloodglucoseandbloodglucoseafter
OGTT. In contrast, the glucose-suppressed GH had corre-
lation coefﬁcients that were much lower (r = 0.32-0.35).
The authors concluded that IGF-I values were more directly
related to changes in soft tissue enlargement and insulin
resistance than GH levels after an OGTT.
Puder et al. [6] measured a symptom index of acro-
megaly consisting of sweating, arthralgias, perception of
soft tissue thickening, and headaches in patients who had
been stratiﬁed into 3 groups using biochemical cure criteria:
group 1 (normal IGF-I and completely normal GH values
after OGTT); group 2 (normal IGF-I but GH did not
suppress to normal); and group 3 (abnormal IGF-I). The
symptom index in group 1 (biochemical cure) was extre-
mely low as was that in group 2. In contrast, patients with
elevated IGF-I (group 3) had markedly increased symptoms
and reduced insulin sensitivity. The authors concluded that
IGF-I was a better indicator of abnormal insulin sensitivity
and the persistence of clinical symptoms.
Dimaraki et al. [7] also evaluated IGF-I and frequent GH
sampling measurements as parameters for the diagnosis of
acromegaly in 16 patients. Subject inclusion criteria were
elevated plasma IGF-I levels and mean plasma GH\5 ng/
ml. The mean GH level was\2.5 ng/ml among 25% of
patients during frequent sampling. The OGTT-GH nadir
was\1 ng/ml in 8 out of 16 patients and in one patient was
less than 0.14 ng/ml cutoff (\0.21 ng/ml cutoff when cor-
rected for assay standards), further demonstrating the limi-
tations of using GH levels as a cutoff. Post transsphenoidal
surgery normalization of IGF-I, occurring in 11 of 14
patients, was associated with improved morbidity despite
normal preoperative GH.Theyconcluded thatIGF-Iwas the
most sensitive and reliable test of active acromegaly.
Pivonello et al. [8] studied the relationship of cardiac
structuralchangeswithpersistenceofabnormalIGF-IorGH
valuesin17patientstreatedwithpegvisomant10 mg/dayup
to 40 mg/day for 6 to18 months. Left ventricular ejection
fraction(LVEF)wasfoundtobethemostsensitivepredictor
of worsening symptoms. Although the value of GH as a
predictor could not be assessed because the GH receptor
antagonist was used, functional improvement in LVEF cor-
related with improved serum IGF-I (R
2 = 0.66). The high
correlation between improvement in LV function and IGF-I
suggests that this would be a good marker for prediction of
disease control.
A study by Colao et al. [9] examined the relationship
between change in tumor size and percent decrease in IGF-
I and GH among 99 patients treated with somatostatin
analogs. The percent decrease in IGF-I was a better marker
of tumor shrinkage (volume on magnetic resonance imag-
ing [MRI]) as compared to the change in GH levels. The
percent change in tumor volume correlated with the percent
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2 = 0.2, P\0.004). This strongly
suggests that the percent decrease in IGF-I was the best
predictor of tumor shrinkage.
Recently a large study by Alexopoulou et al. reported
on all non-cured patients (229 patients) in the Belgium
acromegaly registry [10]. Disease was classiﬁed as con-
trolled versus active depending upon symptomatic index
and other indices, such as continued acral growth or tumor
enlargement. Concordance between IGF-I and GH was
observed among 65% of the patients (35% with both GH
and IGF-I high, whereas the other 30% had controlled
disease and normalization of both parameters). Discordant
values were observed in the remaining 35% of the patients
(24% (n = 55) with persistent abnormally high IGF-I
levels in the presence of controlled GH and 11% (n = 25)
with high GH levels in the presence of a normal IGF-I).
Importantly, the authors felt that the subgroup with high
GH and normal IGF-I levels were for the most part well
controlled in that they had a normal OGTT and an absence
of anthropometric or radiologic indication of disease pro-
gression. Several of these subjects were younger women
who were still having menstrual cycles suggesting that
gonadal steroids might be the cause of discordance
between IGF-I and GH values. In contrast, patients with
elevated IGF-I levels had a worse metabolic proﬁle and
other evidence of disease progression. The authors con-
cluded that measurement of IGF-I was a more accurate
index of active disease and a worse outcome.
Three studies reported QOL measurements and the rela-
tionshipbetweenthemandbothGHandIGF-Ivaluesduring
treatment. Paisley et al. [11] found a correlation between
decreasedIGF-IandoverallimprovementinQOLamong56
patients who were administered the AcroQol questionnaire
(where the correlation coefﬁcient between the change in
QOL and change in IGF-I was r =- 0.36, P\0.006).
However, GH was not measured in these subjects.
Kauppinen et al. [12] measured health-related QOL
among 231 subjects at follow-up, with a mean of 11.4 years
post initial therapy, using a 15-dimension instrument (15D).
The best QOL scores were achieved when GH was sup-
pressed post OGTT to between 0.3 lg/l and 1 lg/l and also
when IGF-I was normal. However, normal IGF-I neither
predicted cure of diabetes mellitus or hypertension nor did it
correlate with an improved QOL score. Basal GH at diag-
nosis and GH levels during treatment also did not correlate.
Twenty-three percent had discordant GH and IGF-I values,
but comparable improvements in QOL.
Trepp et al. [13] compared QOL among 33 patients with
treated acromegaly. IGF-I was found to be a statistically
signiﬁcant predictor in improvement in health-related QOL
per the total AcroQol score (mean of -0.8% per 10 ng/ml
increase in IGF-I, 95% conﬁdence interval (CI), -1.4–0.1,
P = 0.018). GH results were not included other than to
report that 18% of subjects had discordant GH and IGF-I
measurements.
Because acromegaly is associated with a 10-year short-
eningoflifespan,atesttopredictthosepatientswhoaremost
likely to have premature mortality would be of great value.
Seven studies have reported the value of GH or IGF-I levels
inpredictingprematuremortalityfromacromegaly,however
only one study formally measured GH and IGF-I in all
subjects. This study reported by Holdaway et al. [14] dem-
onstrated that both GH suppression and IGF-I normalization
correlated with improved mortality rates. Subjects with a
raised IGF-I greater than the 95% conﬁdence interval had a
3.4-fold increased standardized mortality ratio (SMR)
whereas those with IGF-I less than 2 standard deviations
below the mean had only a 1.2-fold increase. Subjects with
elevated GH showed a 2.6-fold increase in SMR if GH was
not suppressible to\5 lg/l. However, if GH was suppress-
ible to less than 2 lg/l, the SMR was statistically signiﬁ-
cantly increased, but only 1.6- fold. Therefore, the degree of
risk was greater with an elevated IGF-I compared with an
elevated GH.
In another publication by Holdaway et al., the authors
performed a meta analysis on all studies that measured the
efﬁcacy of GH or IGF-I to predict mortality during follow-
up treatment [15]. This study showed that the SMR was
signiﬁcantly elevated for increased IGF-I in 6 of 7 reported
studies, however 95% conﬁdence interval crossed the line
of unity in 3 of 6. A normal IGF-I also predicted no increase
in mortality in 7 of 7 reported studies. In contrast, GH
values were reported to show an increased SMR in 8 of 10
studies and 4 of 10 crossed the line of unity.
It should be noted that use of somatostatin analogs may
complicate the interpretation of GH suppression tests and
result indiscordance between GH and IGF-I levels. This may
be because GH does not always suppress in response to glu-
coseinthepresenceofsomatostatinanalogs,orthattreatment
with somatostatin analogs may exert a direct effect on liver
production of IGF-I. Therefore, caution has to be used in
interpretingsomeIGF-Iassays.BecauseIGF-Ivarieswithage
and BMI, a large number of normative subjects have to be
used in order to obtain reliable normal reference ranges [16].
Grading of evidence
Approximately half of the Summit panelists (56%) con-
cluded the evidence available was Category II, 33% con-
sidered it be Category III, and 11%, Category I (Table 2).
Level of support
All Summit participants voted to accept the statement
although 78% had some reservations. Survey results
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123revealed that community physicians in endocrinology and
neurosurgery felt similarly: 84% voted to accept the
statement completely or with some reservations; 10% with
major reservations; and the remaining 6% rejected the
statement with reservations (Fig. 2).
Discussion
As suggested by Summit panel voting and survey
participants, the value of IGF-I in monitoring for effective
control of acromegaly is supported by a growing body of
evidence. Panelists suggest that reservations regarding the
statement’s validity stem more from the lack of normative
data required for optimizing usefulness of IGF-I assays in
clinical practice than from the statement itself.
Future direction
In summary, several studies have demonstrated the efﬁcacy
of both GH and IGF-I measurements in monitoring acro-
megaly. The evidence currently suggests that elevated
IGF-I is a better predictor of persistent symptoms and
signs, indicating a need for further therapy.
Both measurements predict an increase in SMR and
therefore,bothwillyieldatleastequivalentinformationwith
regard to long-term increased mortality risk. For these rea-
sons, it is recommended that both measurements be per-
formed in post-treatment acromegalic subjects at least once.
If the results are discordant, IGF-I should be followed as an
indicator for a need for treatment of persistent symptoms,
and either IGF-I or GH can be followed as an indicator for
need for treatment reducing risk of premature mortality.
Because of the importance of IGF-I assays in the treat-
ment of acromegaly, individual IGF-I assays must provide
more uniform scientiﬁcally validated standards and robust
normative data. In addition, although gender effects clearly
inﬂuence IGF-I levels, available assays do not provide
normative data based on gender or use of gonadal steroid
hormones.
Statement 2: a GH of £1.0 lg/l as a random
measurement or as a nadir after an oral glucose
tolerance test correlates with disease control in patients
with acromegaly
Rationale and deﬁnition of statement
Patients with acromegaly have increased mortality and
morbidity. Multiple modalities are now available for the
treatment of acromegaly, including surgery, irradiation
(conventional and stereotactic), and medical. The ultimate
goal of treatment is resolution of symptoms, control of
tumor mass and normalization of mortality. However,
because most tumors are macroadenomas and often inva-
sive, complete surgical cure is rarely achieved.
It is important to determine the levels of GH and/or IGF-I
that are associated with improvement of the increased mor-
tality and morbidity. This assesses the strength of evidence
supporting the assertion that a GH of B1.0 lg/l as a random
measurement or as a nadir after an OGTT correlates with
disease control in patients with acromegaly and, therefore,
should be a goal of therapy.
Literature search
Because the evidence of disease control is by deﬁnition the
normalization of mortality and resolution of symptoms, a
PubMed database search to identify studies related to
morbidity and mortality in patients with acromegaly was
completed on October 2008. The search terms used were
‘‘acromegaly,’’ ‘‘mortality,’’ and ‘‘morbidity.’’ Reference
lists of pertinent articles were also reviewed to see if
studies missed by the PubMed search were appropriate for
inclusion. Studies that assessed the morbidity and mortality
Table 2 Summit panel voting
and grading schemes
Category Nature of evidence
I Evidence obtained from at least 1 well-designed, randomized, controlled trial
II Evidence obtained from well-designed cohort or case–control studies
III Evidence obtained from case series, case reports, or ﬂawed clinical trials
IV Opinions of respected authorities based on clinical experience, descriptive
studies, or reports of expert committees
V Insufﬁcient evidence to form an opinion
Individual level of support (Panel members)
1 Accept recommendation completely
2 Accept recommendation with some reservations
3 Accept recommendation with major reservations
4 Reject recommendation with reservations
5 Reject recommendation completely
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123of cohorts of acromegalic patients longitudinally and cor-
related these outcomes with GH and IGF-I levels were
selected. None of these were controlled studies in which
some patients are not treated. Most compared morbidity
and mortality in acromegalic patients to age-adjusted and
sex-adjusted controls living in the same area/country and
then stratiﬁed patients by GH and IGF-I levels.
Evidence
Increased mortality in acromegaly
Although many studies have reported increased mortality in
patients with acromegaly, there have not been any in which
patients with acromegaly were randomized to treatment
versus no treatment and then followed over time. In all
series, patients were treated by a variety of modalities and
then mortality rates were computed as SMRs compared to a
matched population without acromegaly. As early as 1980,
Alexander et al. reported an SMR of 3.3 in 164 patients with
acromegaly, with the increased deaths being attributable to
cerebrovascular, cardiovascular, respiratory, and oncologic
causes [17]. Holdaway reviewed the literature in 2007,
ﬁnding 18 series in which the SMR was reported [18]. In
this review, the SMR ranged from the 3.3 reported by
Alexander et al. [17] to 1.16 reported by Kauppinen-
Makelin et al. [19], with the average for the series being
approximately 2.0 [18]. Increased mortality rates in patients
who had received radiotherapy as part of their treatment
were reported frequently [18]. Some studies also showed
increased mortality rates in subjects with diabetes and
hypertension and in those with delays between diagnosis
and treatment [14]. Overall, there appeared to be
improvement in outcomes over time, with lower mortality
rates in more recent studies compared to older ones [18].
This is likely due to better methods of treatment, improved
treatment of comorbidities, the use of somatostatin analogs,
and increasingly stringent hormone goals for treatment [18].
Growth hormone goal of\2–2.5 lg/l
ControlofGHhasbeenatreatmentgoalforalmost20 years.
However,therehasbeennoconsensusinhowtheGHshould
be measured, hampering the ability to compare data from
different studies. Methods include obtaining samples over
the course of several hours and then averaging the results
(‘‘day curve’’). Alternatively, an OGTT is performed and
only the nadir GH is reported. In other studies, a ‘‘random’’
GH measurement is obtained, although this was often done
fasting in the morning. Further complicating this issue are
changes in GH assays over the past two decades, with
improvement in sensitivity as they changed from the
standard radioimmunoassay (RIA) employing polyclonal
antibodies to current chemiluminescence methods employ-
ing monoclonal antibodies [20]. Although centers in most
countries have reported GH values in mass units of lg/l,
centersintheUnitedKingdomusuallyreportedGHvaluesas
mU/l. Conversion values to mass units were not always
includedinreportsandnotallassayswereequivalentinthese
conversion values. In most of the discussion to follow, ran-
dom GH measurements were performed using older RIAs.
In the early 1990s, the goal for treatment was GH
level\5.0 lg/l. Bates et al. reported that in their long-term
follow-up study of 79 patients, those with GH levels
[5 mU/l using a 5-point day curve had an SMR of 3.32,
whereas those with GH levels\5 mU/l had an SMR of
1.42 [21]. Unfortunately, they did not report the conversion
value for their assay in terms of mass units [21]. In a study
of 254 patients who had undergone transsphenoidal sur-
gery, Abosch et al. found that the SMR for individuals with
aG H [5.0 lg/l was 3.10 whereas it was 1.00 for those
with GH\5.0 lg/l [22].
More recent studies have addressed beneﬁts of lowering
GH levels to less than 2.0–2.5 lg/l. In a retrospective
analysis of 1362 patients from 15 centers in the United
Kingdom, Orme et al. found SMRs of 1.10 (CI, 0.89–1.35),
1.41 (CI, 1.16–1.68), and 2.12 (CI, 1.70–2.62), in patients
withGHlevelsof\2.5,2.5–9.9,and C10 lg/l,respectively
[23]. When they looked at the causes of mortality, a linear
trend forincreasingmortality with increasingGHlevelswas
found for cardiovascular and malignant disease, but not for
respiratory or cerebrovascular disease [23]. In a Canadian
studyof103patients,Beauregardetal.foundthatpatientsin
remission, deﬁned as a random GH\2.5 lg/l or a glucose
suppressed GH\1 lg/l and a normal IGF-I, had an SMR of
0.88,whereasthosenotinremissionhadanSMRof4.8[24].
Similarly, Kauppinen-Makelin et al. found that of 334
Finnish patients, those with a random GH\2.5 lg/l had an
SMR of 0.48 (CI, 0.23–0.88) whereas those with lev-
els C2.5 lg/l had an SMR of 1.63 (CI, 1.10–2.35) [19].
Mestro ´n et al. reported a retrospective analysis of 1219
Spanish patients that used GH (basal or OGTT-derived
nadir\2 ng/ml) with or without concomitant normalized
IGF-I levels or normalized IGF-I alone as the criteria for a
cure. Signiﬁcantly more people who had never achieved a
basalGH\2 lg/ldied(7.2%ofuncuredpatients)compared
with those who did obtain a basal GH\2 lg/l (1.3% of
cured patients), P\0.001). Similar numbers were reported
when the cure was deﬁned using OGTT-derived GH
nadir\2 lg/l as the cutoff [25]. Unfortunately, they did not
calculate SMRs in their study [32]. On the other hand, in 3
smaller studies of Swiss (n = 94) [26], Japanese (n = 154)
[27], and Dutch (n = 164) [28] acromegalic patients, only
small nonsigniﬁcant differences in SMR with GH levels
above and below the 2.5 lg/l cutoff were found.
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levels\1 lg/l resulted in a further decrease in mortality. In
their study of 208 acromegalic patients from New Zealand,
Holdaway et al. found that the SMRs for GH levels\1,\2
and\5 lg/l were 1.1 (CI, 0.5–2.1), 1.6 (CI, 0.9–3.0), and
2.5 (CI, 1.6–3.6) [14]. The value for\2 lg/l was not sig-
niﬁcantly increased and not statistically different from that
for\1 lg/l. Ayuk et al. analyzed their database of 419
acromegalic patients from the West Midlands region of the
United Kingdom, ﬁnding a clear but only borderline sta-
tistically signiﬁcant (P = 0.068) trend mortality beneﬁt
with a GH cutoff of 2 lg/l [29]. Furthermore, they found
not even a trend towards further beneﬁt using a GH cutoff
of 1 lg/l [29].
Recently, Holdaway et al. performed a formal meta-
analysis of the effect of lowering GH levels to\2.5 lg/l,
abstracting data from the studies mentioned above. In this
analysis of 10 studies, they found a pooled SMR of 1.9 (CI,
1.5–2.4) for patients with ﬁnal GH levels[2.5 lg/l,
whereas the pooled SMR was 1.1 (CI, 0.9–1.4) for those
with ﬁnal GH levels\2.5 lg/l (Fig. 1)[ 15].
Interestingly, in this meta-analysis, there was a clear
improvement in the overall SMR over time. The SMR for
the 6 studies in which the mean year of patient entry was
prior to 1984 was 2.2 (CI, 1.8–2.8) and that for the 7
studies in which the mean year of patient entry was after
1984 was 1.3 (CI, 1.1–1.6) [15].
Grading of evidence
Based on a review of the 11 studies presented above as well
asthemeta-analysisperformedbyHoldawayetal.[15],the9
members of this workshop varied widely in opinion
regarding the nature of the evidence to support/refute this
statement.Grades2and5werechosenby22%eachwhereas
44% chose grade 3 and 11% chose grade 4. See Table 2.
Level of support
Seventy-eight percent of the Summit participants voted to
accept the statement, primarily with major reservations,
compared with 94% of the respondents surveyed, who
accepted it either completely or with some reservations. It
was rejected by 22 and 6% of the Summit participants and
survey participants, respectively. More detailed results can
be found in Fig. 2.
Discussion
Majorreservationsregardingtheacceptanceofthestatement
became evident.Panelistsidentiﬁedseveralshortcomingsof
4.6 2.0 (1.0, 4.0)
6.3 3.1 (1.5, 6.4) 
9.9 1.4 (1.2, 1.7)
2.9 1.6 (0.6, 4.3)
5.5  4.8 (2.7, 8.7)
9.0 1.4 (1.1, 1.8)
4.0 1.5 (0.7, 3.2)
8.0 2.3 (1.6, 3.3)
Bates 1993
Bates 1993
Abosch 1998
Abosch 1998
Orme 1998
Orme 1998
Arita 2003
Arita 2003
Beauregard 2003
Beauregard 2003
Ayuk 2004
Blermasz 2004
Blermasz 2004
Holdaway 2004
Holdaway 2004
7.8 1.6 (1.1, 2.3) Kauppinen-Makelin 2005
Kauppinen-Makelin 2005
3.6 1.4 (0.6, 3.3) Trepp 2005
Trepp 2005
59.6 1.9 (1.5, 2.4) Final GH >2.5 µg/L
Final GH <2.5 µg/L
P<0.00001
2.6 1.4 (0.5, 4.0)
6.2 1.0 (0.6, 1.7)
2.0 1.1 (0.3, 3.8)
2.7 1.1 (0.4, 3.1)
2.4 0.9 (0.3, 2.7)
7.6 1.2 (0.8, 1.8)
7.3 1.5 (1.0, 2.3)
5.5 0.5 (0.3, 0.9)
4.0 1.3 (0.6, 2.8)
40.4 1.1 (0.9, 1.4)
P=0.50
1.5 (1.2, 1.8)      P<0.0001 Total
Test for heterogenicity: I
2 = 59%, P<0.01
Study
Standardized Mortality Ratio
(Random) (95% CI)
Weight
(%)
Favours decreased
mortality in acromegaly
Favours increased
mortality in acromegaly
0.5 1 2 5 10
Fig. 1 Pooled standardized
mortality ratios (SMRs) in
studies of acromegaly grouped
by GH level at ﬁnal follow-up
[15].  European Society of
Endocrinology (2008).
Reproduced by permission.
Note: Data are SMR (95%
conﬁdence interval)
272 Pituitary (2010) 13:266–286
123available data, which included variability in current GH
assays as well as changes in GH assays and treatments over
time. Others included lack of control or data on comorbidi-
ties and cause of death. There were very little data available
examining the use of OGTT-derived GH values instead of
random or basal GH values. Therefore, this aspect of the
statement was not well supported.
As mentioned earlier, the presence of disease control
was measured by the mortality rate, despite the possibility
that symptom control or QOL might also be considered a
component of disease control. However, all of the long-
term outcome data primarily focuses on mortality rather
than morbidity. The few data available suggest that mor-
bidity tracks very closely with mortality with respect to GH
levels [30, 31] and that there is no need to use different
criteria for morbidity compared to mortality.
Data reviewed supports a cutoff of 2.5 lg/l using older
assays. Furthermore, Summit participants recognized that
Summit Panel             Survey*
1
2
3
4
5
Percentage
100 90 80 70 60 50 40 30 20 10 0
Statement 1: An IGF-I value that is 
normal for age and gender signifies 
control of acromegaly.
Statement 2: A GH of <1.0 µg/L as a 
random measurement or as a nadir 
after an oral glucose tolerance test 
correlates with disease control in 
patients with acromegaly.
Statement 3: GH levels sampled at 
any time interval are better predic-
tors of control of acromegaly and 
related morbidity than IGF-I levels.
Statement 4: The administration of 
somatostatin analogs prior to 
transsphenoidal surgery improves 
surgical outcome and disease 
morbidity associated with 
acromegaly.
Statement 5: The dosing interval of 
a somatostatin analog can be 
extended beyond once every 4 
weeks without compromising 
disease control in patients with 
acromegaly.
Statement 6: A monthly injection of 
the depot form of lanreotide or 
octreotide results in consistent 
control of hormone levels and 
symptoms in patients with carcinoid 
syndrome.
Summary
Footnote
1–Accept completely
2–Accept with some reservations
3–Accept with major reservations
4–Reject with reservations
5–Reject completely
*Survey participants included a total 100 community-based medical specialists
(75 endocrinologists; 2 neuroendocrine physicians; 23 neurosurgeons).
IGF-I=insulin-like growth factor-I; GH=growth hormone.
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Fig. 2 Comparison voting between summit panel and surveyed clinicians for 6 statements related to the current treatment of acromegaly and
carcinoid syndrome
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123the statement’s cut-off GH level of 1 lg/l using current
assays approximates the GH levels of about 2–2.5 lg/l
using older RIAs in the studies reviewed. Thus, they rec-
ommended that a current goal of therapy for patients with
acromegaly should be GH\1 lg/l since a\2.5 lg/l (as
assessed by older assays in past studies) correlated with
normalization of the high mortality rate associated with
acromegaly.
Future direction
Panelists stressed the importance of the differences
between the older and newer GH assays when trying to
formulate goals for treatment. Not only are the assays of
different sensitivities, but they also vary in how they cor-
relate with GH standard preparations. It will be important
in future studies to specify the type of GH assay used and
how it relates to appropriate GH standards. There was no
uniformity among the Summit participants as to whether a
single random GH specimen versus GH after oral glucose
(or GH day curves) should be obtained. However, from a
practical point of view, it was recognized that a single
specimen is the most practical way to follow patients over
time, and that a fasting specimen is preferred to a ‘‘ran-
dom’’ specimen. It was also recognized that in earlier
studies, determination of cause of death was often declared
according to local custom and regulations. For future
studies, standardized methods should also be used in
determining mortality and causes of death as well as
morbidities. Every effort should also be made to aggres-
sively manage the comorbidities of acromegaly since those
conditions have the potential to impact outcomes as does
the management of GH and IGF-I levels.
Statement 3: GH levels sampled at any time interval are
better predictors of control of acromegaly and related
morbidity than IGF-I levels
Rationale and deﬁnition of statement
Determination of the best methods for monitoring treat-
ment effectiveness is essential for optimal care of patients
with acromegaly. While control of the disease and related
morbidity are the true treatment goals, methods of pre-
dicting and measuring the adequacy of treatment depend on
the use of biochemical measurements such as serum GH
and IGF-I levels as interim markers of success or failure.
Whether one marker extends advantages over the other,
perhaps even to the extent of eliminating the need for a
second marker, is the topic being considered here. How to
interpret discrepant results between these parameters is
also discussed here since such discrepancy is not rare.
Literature search
A literature search in PubMed was performed in October
2008, revealing 94 articles relating to GH, IGF-I, acro-
megaly, morbidity, and mortality. Of these, 11 were con-
sidered to be most pertinent to the statement.
Evidence
A recent review articlereporteda meta-analysis of mortality
studies, which included data from 4806 patients and 1116
deaths [15]. It demonstrated that mortality rates in patients
with random serum GH\2.5 lg/l (measured primarily with
RIA) despite treatment were close to expected (SMR 1.1
[95%CI,0.9–1.4])incontrasttopatientswithGH[2.5 lg/l
(SMR of 1.9 [95% CI, 1.5–2.4]). The authors concluded that
the random serum GH cutoff should be lowered to 1 lg/l if
modern sensitive immunoassays are used. Findings were
similar when IGF-I was the criteria, with an SMR of 1.1
(95% CI, 0.9–1.4) in patients with serum IGF-I normal for
age and sex at last follow-up after treatment compared with
2.5 (95% CI, 1.6–4.0) in those with elevated IGF-I levels.
In the Belgian registry enrolling 229 non-controlled
patients [10], 35% had a discordant GH and IGF-I pattern.
Young estrogen-sufﬁcient females tended to make up the
group of the high GH phenotype, suggesting that age,
gender, and estrogens have a role in this divergence. On the
other hand, the high IGF-I phenotype was associated with a
worse metabolic proﬁle suggesting that it might indicate
persistent active disease.
Another study presented data from 166 patients who
underwent multiple GH and IGF-I testing as well as an
OGTT following either surgery or during treatment with
somatostatin analogs or dopamine agonists [32]. Discor-
dant results of OGTT testing were noted in 32, 48, and 18%
in the 3 treatment groups, respectively. In patients studied
during somatostatin analog therapy, 42% of tests were
discordant with a pattern of normal IGF-I and GH
nadir[1 lg/l, while only 4% of tests had similar discrep-
ancy in patients treated with dopamine agonists. The dis-
cordance between GH and IGF-I control in this treatment
group were similar when fasting GH levels were used,
leading to the conclusion that both basal and GH nadir
levels are highly discordant with IGF-I levels during
somatostatin analog therapy (signiﬁcantly different com-
pared with surgery group [P = 0.03] and dopamine agonist
group [P\0.001]) and that OGTT is not useful in
assessing biochemical control in these subjects [32].
There are several studies that investigate predictors of
discrepancy between GH and IGF-I. As already mentioned,
estrogen-sufﬁcient women or those receiving estrogen
therapy for hypogonadism are more likely to have elevated
GH levels, both in a fasting state [10, 33, 34] and after
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123glucose load [1] in presence of normal IGF-I levels. Indeed,
withdrawal of oral estrogen replacement during chronic
treatment with somatostatin analogs was associated with
signiﬁcantly lower GH levels and higher IGF-I levels than
during treatment [33]. A gender difference in the relation-
ship between serum GH and IGF-I in 153 patients with
active acromegaly was conﬁrmed in another study, where
results were again consistent with relative GH resistance
in normal and GH-deﬁcient females; these ﬁndings were
considered partially mediated by estrogens. It was estimated
that serum IGF-I values for a given serum GH value were
82 ng/ml less in females than in males (P\0.02; 95% CI,
15.2–149). The mean serum IGF-I for a given GH value was
130 ng/ml lower in females on oral estrogen therapy than
in males (P = 0.01; 95% CI, 29.8–230.2), but were only
60 ng/ml less than the other 45 females (P = 0.2) [35].
Similarly, older patients, as well as those with a higher
BMI, generally had lower GH levels, either as fasting or
post-glucose values [1, 36]. In patients aged above
60 years, cutoff GH levels as low as 1.4 lg/l (as a fasting
sample) and 0.5 lg/l (as a post-glucose nadir level) were
proposed [36]. However, another study found GH levels
(either basal or post-glucose nadir) to be no different based
on age or gender [37]. It is evident that normative GH data
still needs to be fully established.
One potential source of bias in analyzing GH values
during treatment of acromegaly is the assay used. A recent
study investigated the measurement of GH during a stan-
dard 75-g OGTT in 46 acromegaly patients and 213 heal-
thy subjects. This study used 3 different commercially
available assays (Immulite [Diagnostic Products Corp., Los
Angeles, CA]; Nichols [Nichols Institute Diagnostika
GmbH, Bad Vilbel, Germany]; and Diagnostic Systems
Laboratories [Sinsheim, Germany]) that were calibrated
against recently recommended GH standards [38]. Although
GH results from all 3 assays strongly correlated with each
other, those obtained with the Immulite assay were 2.3- and
6-fold higher than those obtained with Nichols or Diagnostic
Systems Laboratories, respectively. Different cutoff limits
(1 lg/l [Immulite] and 0.5 lg/l [Nichols]) were found to
identify 95% of patients with active disease and 78–80%
of patients in remission [38]. The authors conﬁrmed that
signiﬁcantly higher basal and nadir GH levels occurred
in healthy females than in males (Immulite 2.2 ± 0.28 vs.
0.73 ± 0.15 lg/l for basal results and 0.16 ± 0.01 vs.
0.08 ± 0.01 lg/l for nadir results; P\0.001, respectively).
Gender-speciﬁc differences were also noted in acromegalic
patients, although not statistically signiﬁcant. Multiple
regression analysis revealed age, BMI, and gender to be
predictors for basal and nadir GH levels, and that post-glu-
cose GH-nadir values (and likely fasting GH values) are
assay-, gender-, age-, and BMI-speciﬁc [38]. These data
indicate that the GH cutoff currently used presents important
drawbacks, explaining the high rate of discrepancy with
IGF-I levels. They also suggest that GH cutoffs should be
age-, gender-, and BMI-related as are IGF-I ranges. More-
over, the data suggested a need for cutoff limits to be assay-
individualized.
These problems in accurately assessing the biochemical
control of acromegaly might explain why some data report
similar clinical improvement in patients both who are well
controlled biochemically and those who are not. Mean daily
GH levels, IGF-I, leptin and lipid levels, glucose, insulin,
and GH nadir during OGTT were measured in 41 patients
post transsphenoidal surgery for a GH-secreting pituitary
adenoma and in 23 patients with naive acromegaly serving
as positive controls [39]. Additionally, insulin resistance
was measured by homeostatic model index (R-HOMA),
body composition assessed by dual-energy X-ray absorpti-
ometry, and left ventricular mass index (LVMi) and cardiac
index (Ci) determined by echocardiography [39]. The
authors reported no difference in cardiac indices, insulin
resistance, body composition, or leptin levels between
patients with complete biochemical remission and those
with inadequately controlled disease after surgery. Cardiac
index was lower in cured patients compared with naive
patients and LVMi was similarly decreased in controlled
(108.4 ± 30 g/m
2; P = 0.015) and inadequately controlled
disease (108.8 ± 30.7 g/m
2; P = 0.03) in comparison with
naive disease (160.3 ± 80.6 g/m
2). In both controlled and
uncontrolled disease, R-HOMA index was lower than
in naive disease (2.2 ± 1.4; P = 0.001 and 3.1 ± 2.0;
P = 0.05 vs. 5.1 ± 3.1) and leptin concentration was
higher (14.9 ± 8.7 lg/l; P = 0.004 and 12.8 ± 7.8 lg/l;
P = 0.05 vs. 7.4 ± 3.8 lg/l) [39]. Cardiac (P = 0.04) and
R-HOMA index (P = 0.009) were independent predictors
of biochemical remission when considered solely on normal
IGF-I. Insulin resistance (P = 0.02) and leptin level
(P = 0.002) were independent predictors of normalized
mean GH values. Accordingly, cardiac indices, insulin
resistance, and body composition were not different in those
patients with complete biochemical remission compared to
those with discordant GH and IGF-I levels [39].
Similarly,inastudywherestrictlycontrolledacromegaly
improving cardiac dysfunction demonstrated that systolic
function at rest was decreased by 18% (P\0.01), LVMi
increased by 40% (P\0.04) and isovolumetric relaxation
time increased by 19% (P\0.01) in patients with active
acromegaly compared with those with inactive disease. No
difference was observed between patients cured after sur-
gery or controlled with somatostatin analogs [40]. The ratio
between early and late diastolic velocity (E/A ratio) using
tissue Doppler imaging was decreased in active acromegaly
compared with inactive (0.75 ± 0.07 vs. 1.24 ± 0.15;
P\0.01), but was higher in surgically cured than in
octreotide-treated patients (1.75 ± 0.41 vs. 1.05 ± 0.1;
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123P\0.01). The fact that acromegalic patients who had been
under long-term control with octreotide were likely to have
diastolic function persistently and signiﬁcantly more
impaired than surgically cured patients suggests the exis-
tence of underlying biological effects of subtle abnormali-
ties in GH secretion. However, a more recent prospective
study [41] did not support the conclusion of the van Thiel
study [40]. Further data on cardiac function are needed.
Grading of evidence
The Summit participants varied in their view of the nature
of evidence as it pertains to the statement. Almost half
(44%) considered it to be of Category III whereas 22%
thought it to consist of Category I and Category II each.
One person considered it to be insufﬁcient to form an
opinion. See Table 2.
Level of support
Eighty-nine percent of the Summit participants voted to
reject the statement compared with 67% of survey partic-
ipants. Summit participants were more likely to reject it
without reservations (Fig. 2).
Discussion
Serum GH measurements taken either at random times or
as part of dynamic testing using the oral glucose suppres-
sion test were found to be indicative of disease control. The
requirement of using both biochemical parameters to
evaluate the activity of acromegaly is still valid. However,
as the evidence demonstrates, there are too many uncertain
aspects of GH testing to allow it a more dominant role in
monitoring treatment of acromegaly.
Future direction
It would be helpful to reanalyze GH cutoff values
according to patient’s gender, age, BMI, gonadal status,
and assay in previous studies, and to perform such analyses
in future studies.
Statement 4: the administration of somatostatin analogs
prior to transsphenoidal surgery improves surgical
outcome and disease morbidity associated with
acromegaly
Rationale and deﬁnition of statement
The use of somatostatin analogs has been demonstrated to
be of beneﬁt to patients with acromegaly. However, the
role of surgical pretreatment in patients destined for
transsphenoidal resection has yet to be deﬁned. Consider-
ation of the inﬂuence of somatostatin analogs on surgical
outcomes, as well as surrogate results that may reﬂect on
outcomes, are addressed here within the context of avail-
able clinical evidence.
Literature search
A literature search via the PubMed database was done in
October 2008. The search terms ‘‘octreotide’’ and ‘‘lanre-
otide’’ using the ‘‘OR’’ function, yielded 6606 articles;
‘‘somatostatin analogs’’ yielded 4594; and ‘‘octreotide,’’
‘‘lanreotide,’’ and ‘‘somatostatin analogs’’ combined by
using the ‘‘OR’’ function yielded 9282 articles. The search
terms ‘‘primary therapy’’ and ‘‘preoperative therapy’’ each
yielded 298,217 and 113,760 articles, respectively; when
these terms were combined using the ‘‘OR’’ function,
400,261 articles were found. The single term ‘‘acromeg-
aly’’ yielded 7447 articles. And, 3 searches of all the listed
terms combined with ‘‘AND’’ resulted in 138 articles.
Upon examination, the search revealed 20 articles relevant
to the statement, including 2 articles found in a hand
review.
Evidence
The ﬁrst studies considered here investigated the basic
question of whether primary therapy with somatostatin
analogs provides effective biochemical control of acro-
megaly. Results of these studies were included here as they
serve as surrogate data for whether or not presurgical
medical therapy is of beneﬁt postoperatively.
In a published review of 24 studies that had been per-
formed through 2005, Melmed et al. summarized the effects
of primary treatment with somatostatin analogs among 424
patients. Thirty-seven percent of patients exhibited signiﬁ-
cant shrinkage, with an average of 50% reduction in tumor
size. One of the studies included in the review was a pro-
spective open label study by Bevan et al. demonstrating that
tumor shrinkage was associated with primary octreotide
therapy in treatment-naı ¨ve patients [42, 43].
Baldelli’s retrospective study among 118 patients pre-
sented compelling data showing non-inferiority of surgery
versus radiotherapy versus primary therapy with lanreotide
over a 24-month period. The ultimate levels of GH and
IGF-I were similar in each group [44].
Three prospective open label studies subsequent to the
2005 critical analysis provided further surrogate data
demonstrating that primary therapy with somatostatin
analogs was associated with tumor shrinkage, and was
effective for biochemical control. Colao et al. showed
reduced tumor volumes in patients with microadenomas as
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123well as macroadenomas [45]. In Cozzi’s report of 67
patients, there was 62% mean tumor volume reduction. In
this group, adenoma mass reduction to an empty sella was
experienced by 11 patients, and cavernous sinus tumor
invasion was resolved in some patients. Tumor shrinkage
was noted to be more marked in younger patients. Most
interestingly, one-third of patients who did not exhibit GH
control still experienced tumor shrinkage. This was the ﬁrst
report of such discordance between tumor shrinkage and
GH control in the literature [46]. Finally, Mercado et al.
concluded that primary treatment with octreotide LAR was
as effective as primary surgical resection [47].
Nine studies were identiﬁed which directly addressed
the question at hand—does preoperative treatment enhance
subsequent surgical outcome? The ﬁrst 5 of these studies
presented here concluded that surgical outcomes are not
enhanced by prior use of somatostatin analogs. Three of
these were prospective but nonrandomized studies by
Biermasz, Kristof, and Plockinger which showed no dif-
ferences in postoperative outcomes in patients pretreated
with short-acting subcutaneous octreotide, or not [48–50].
Plockinger’s study also showed no differences in short-
term or long-term GH control or in pituitary function
parameters in the 2 groups [50].
Losa et al. reported a retrospective case-matched study
with 286 patients that showed no difference in surgical
outcomes. Patients were pretreated with any of different
preparations of both octreotide and lanreotide for varying
lengths of time [51]. Abe and Ludecke also showed data
from reported results of a retrospective study among 147
patients who had received subcutaneous octreotide for at
least 3 months preoperatively. The remission rates were
lower in the medically pretreated group (69%) when
compared with the surgery-only group (77%), although the
differences did not achieve statistical signiﬁcance [52].
The ﬁrst of 4 studies that demonstrated improved sur-
gical outcomes following prior treatment with somatostatin
analogs is that of Barkan’s, where 10 patients with
untreated invasive pituitary macroadenomas were treated
prospectively with subcutaneous octreotide for 3 to
30 weeks. Remission rates were signiﬁcantly enhanced
compared with those achieved in historical controls where
patients were operated on by the same surgeon [53]. Ste-
venaert et al. performed a prospective open label study
among 48 patients where preoperative octreotide was
compared with surgery only. Remission rates were signif-
icantly higher in the group receiving octreotide pretreat-
ment compared with surgery only, especially among
patients with enclosed adenomas (89 versus 69%;
P\0.05), but outcome differences were not observed in
the group of patients with invasive adenomas [54].
Colao et al. performed a retrospective study using a
control group from the same 5-year time period which
utilized the same surgical team. Patients in the pretreatment
group received octreotide for 3 to 6 months prior to sur-
gery. Clinical and surgical outcomes were both enhanced in
the pretreated group. Postoperative circulating GH and
IGF-I levels were controlled in 11 untreated (29.7%) versus
12 octreotide-treated (54.5%) patients (P = 0.005), respec-
tively. Preoperatively, considerable tumor shrinkage was
observed in 5 of the 22 patients and electrocardiogram
(ECG) abnormalities normalized in 67% of patients pre-
treated with octreotide [55].
Carlsen’s report details the only study that directly
addressed the statement. This prospective, randomized,
controlled study compared outcomes in patients who had
received a 6-month or longer course of octreotide LAR
preoperatively with those who underwent surgery without
prior medical treatment. All patients were treated within a
closed healthcare system that provided consistent method-
ologiesforMRIsandlaboratoryassays,andutilizedthesame
surgical teams. A substantially greater number of pretreated
patients experienced biochemical remission compared with
surgery alone (50 vs. 16%, P = 0.017). Despite the study
randomization, the pretreatment group was found to exhibit
signiﬁcantly lower baseline serum IGF-I levels as compared
with the surgery only group [56]. The effects of this con-
founding factor on the ﬁndings are not known.
Finally, the question can be asked—is there or could
there be a potential difference between octreotide and
lanreotide in terms of effects on surgical outcomes? Based
on several studies directly comparing effects of octreotide
LAR and lanreotide depot as reviewed by Murray et al., no
difference was found between the 2 molecules in regard to
GH and/or IGF-I responsiveness [57].
Grading of evidence
All members of the Summit agreed that there was well-
designed evidence regarding the statement. Seventy-eight
percent voted that the evidence was Category I while 22%
indicated that it was Category II (Table 2).
Level of support
There was unanimous acceptance of the statement among
the Summit panelists, although none completely accepted
it. Seventy-eight percent expressed some reservations,
whereas 22% had major reservations. In contrast, 19% of
survey participants rejected the statement. Voting details
can be found in Fig. 2.
Discussion
The level of support for the statement among the Summit
panelists paralleled the grading of the evidence, suggesting
Pituitary (2010) 13:266–286 277
123the major reservation by 22% was associated with the
perception of a lesser quality of available evidence.
Although there was a randomized controlled study (RCT)
with results that supported the validity of the statement, the
presence of confounding factors in that study (i.e, signiﬁ-
cantly lower baseline serum IGF-I levels in the pretreat-
ment group) [84] was considered by Summit members to
have portended an enhanced subsequent control rate in that
group.
Another point expressed by Summit participants related
to their voting results was that the statement did not dif-
ferentiate between microadenomas and macroadenomas.
Participants tended to agree that while the evidence sup-
ported the use of somatostatin analog therapy among
patients with macroadenomas and destined for surgery, the
recommendation to pretreat microadenomas was not well
supported by the published results.
Since the most robust study offering evidence in support
of the value of pretreatment with somatostatin analogs was
published only months before the survey, it is possible that
a lack of awareness of that RCT may have inﬂuenced the
voting by survey participants.
Future direction
Clearly, more studies are required to support the role of
therapy with somatostatin analogs among patients destined
for surgery. Pretreatment use of somatostatin analogs has
been examined largely in nonrandomized studies with
several methodological shortcomings. Future studies need
to speciﬁcally address the use of the products that are
currently available, particularly octreotide LAR and lan-
reotide depot, since the results obtained with these long-
acting preparations may differ from those observed with
the older shorter-acting preparations. Furthermore, the
studies should include a sufﬁcient follow-up period to
monitor for true long-term outcomes, as well as be better
controlled for the respective surgeon, biochemical assay
variation, and methods of tumor volume determination.
Until then, the evidence suggests that use of somato-
statin analogs prior to transsphenoidal surgery is of value,
particularly in patients harboring macroadenomas.
Statement 5: the dosing interval of a somatostatin
analog can be extended beyond once every 4 weeks
without compromising disease control in patients
with acromegaly
Rationale and deﬁnition of statement
Extending the dosing interval of every four week prepa-
rations of somatostatin analogs offers the advantage of
fewer injections, beneﬁting the patient with less discomfort
and inconvenience and cost reduction.
Literature search
In order to examine the empirical evidence available to
support or refute this statement, a literature search was
conducted in October 2008 via PubMed using search terms
detailed in Table 3. After review, 7 articles were deter-
mined to be pertinent to the statement. One additional
article that was published in December 2008 was identiﬁed
after completion of the search.
Evidence
All 8 of the studies found to be pertinent to the statement
were prospective and open-label, and speciﬁcally addres-
sed the issue of extended dosing with various somatostatin
analogs in patients with acromegaly. All assessed disease
control by monitoring either biochemical response or
symptom control or both. Most involved fewer than 30
patients.
Jenkins et al. noted that GH and IGF-I control was
maintained in some patients even at 6 weeks after the ﬁnal
dose of octreotide LAR. Mean GH was\5 mU/l in 13 and
12 out of 18 patients at 4 and 6 weeks, respectively. IGF-I
was normalized in 12 and 11 out of 18 patients, respec-
tively, suggesting that octreotide LAR dosing intervals
could be extended to 6 weeks in some patients [58].
Biermasz et al. studied the effectiveness of octreotide
LARgivenat6-weekintervalsinacohortof14patientswith
active acromegaly who were already controlled (deﬁned as
GH\5 mU/l and normal IGF-I) while receiving octreotide
LAR every 4 weeks for at least 3 months. During a with-
drawal period, mean GH increased from 1.68 mU/l at
4 weeks, 2.57 mU/l at 6 weeks, and 2.89 mU/l at 8 weeks
after administration (P = 0.04, 4 vs. 6 weeks; and P\
0.001, 4 vs. 8 weeks). The mean GH level was\5 mU/l in
all patients at all time points, except in one patient at
8 weeks. IGF-I levels also remained normalized in all
Table 3 Literature search strategy
Search Textwords # of articles
Search 1 Somatostatin analogs or lanreotide or
octreotide
9615
Search 2 Drug administration schedule
or interval
276,345
Search 3 Acromegaly 7404
Search 4 Combine above
with ‘‘and’’
88
Search 5 Limit results from
Search 4 (English and Human)
78
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123patients. There was no signiﬁcant change in symptom or
QOL scores. Mean drug level decreased from 1610 ng/l to
1045 ng/l and 559 ng/l at 2, 6, and 8 weeks, respectively
[59].
Following the 8-week withdrawal period of the study,
patients resumed their previous dose of octreotide LAR,
but the drug was administered every 6 weeks. Mean GH
remained\5 mU/l in 13 out of 14 patients at 26 weeks,
and in 13 out of 13 patients at 44 weeks. IGF-I was
normal in 11 out of 14 patients at 26 weeks, and in 9 out
of 13 patients at 44 weeks. Mean serum octreotide con-
centration did not change signiﬁcantly between weeks 6
and 26 or weeks 6 and 44. Mean QOL score decreased
from 5 to 4, and mean symptom score did not change at
all. The authors concluded that octreotide LAR dosing
intervals can be extended to 6 weeks in some patients, but
that careful monitoring (clinical and biochemical) is
warranted [59].
Dosing intervals of octreotide LAR were adjusted in
Turner’s study with 22 patients, based upon mean GH
levels of\5 mU/l. The dosing interval was success-
fully increased beyond 4 weeks in 20 out of 22 patients; 6
patients were extended to 8 weeks, and 3 patients to
12 weeks. Despite the success with increased dosing
intervals in some patients, there was no relation-
ship between the ability to increase intervals and pre-
treatment mean GH or IGF-I, age, or previous treatments,
limiting the ability to predict which patients could
successfully receive octreotide LAR at longer dosing
intervals [60].
Van Thiel et al. reported the duration of action of lan-
reotide depot, an every 4 week preparation. Seven patients
with active acromegaly who were already receiving
octreotide LAR (average duration 2.8 years) with good
response were crossed over to lanreotide depot and the
dose was titrated to fasting GH\5 mU/l and IGF age-
matched normal. Although the dosing intervals were not
extended with either octreotide LAR or lanreotide depot,
GH and IGF-I control was evaluated after a 6-week with-
drawal period following at least 1 year of treatment with
each drug. While 3 out of 7 patients in each treatment
period achieved control of both GH and IGF-I at 4 weeks,
only one in each treatment period remained controlled at
6 weeks [61].
A cross-over study by Lucas et al. later examined var-
ious ﬁxed dosing intervals of the same 120 mg dose of
lanreotide depot in 98 patients who had already been
demonstrated to be responsive to somatostatin analogs. The
patients were ﬁrst treated with lanreotide microparticles
(LAN MP) 30 mg, with the dose interval initially being
adjusted to optimally control their disease. The intervals
were kept constant for at least the 2 months prior to being
switched over to lanreotide depot. The total monthly dose
was maintained and the dosing interval was determined
by the LAN MP dosing interval. Lanreotide depot inter-
vals were 4, 6, or 8 weeks if the LAN MP intervals had
been 7, 10, or 14 days, respectively. GH\2.5 ng/ml were
observed with lanreotide depot in 54% of patients and in
46% of patients while on LAN MP. Symptoms were also
better controlled with lanreotide depot at 4 to 8 week
intervals compared with LAN MP at 7 to 14 day intervals
[62].
Abrams et al. reported on a study examining different
dosing intervals of lanreotide depot in 21 patients who had
been receiving 60 mg, 90 mg, or 120 mg at 4-week inter-
vals. Intervals were extended to 6 weeks among patients
well controlled on their ﬁxed dose (n = 9). Those poorly
controlled on a ﬁxed dose every 4 weeks either underwent
a dose increase or an interval decrease if they were already
at the maximum dose (120 mg). Patients with reasonably
good control with their previous ﬁxed dose (deﬁned as
IGF-I normal and GH between 1.7 and 2.5 lg/l) underwent
both a 30 mg dose increase and an interval increase to
6 weeks. 7 out of 9 patients who were in good control at
baseline remained so at 36 weeks. In contrast, only 1 of 12
patients who were not previously in good control had
normalized IGF-I and GH at 36 weeks, despite dosing
intervals of 3 weeks [63].
Finally, Ronchi et al. studied 23 patients who had
previously received octreotide LAR every 4 weeks with a
GH reduction at least 50% of pretreatment values. After a
3-month washout period, lanreotide depot 120 mg was
administered every 6 weeks for 4 cycles (treatment period
1). Dosing intervals based on GH level responses were
then increased (6 patients), decreased (12 patients), or
maintained (6 patients) for an additional 2 to 3 cycles.
The mean biochemical levels and number of well-con-
trolled patients were similar at the end of octreotide LAR
treatment and each of the treatment periods, suggesting
that extended dosing intervals of lanreotide depot can be
extended beyond 4 weeks in approximately half of the
patients [64].
A recent study by Colao et al. examined biochemical
control and tumor shrinkage associated with lanreotide
depot treatment in 26 patients with newly diagnosed
acromegaly. Initial dose intervals of lanreotide depot
120 mg were increased from 4 weeks to 6 or 8 weeks, as
permitted by maintained control. The ﬁnal dosage interval
was 4 weeks in 35% of patients; 6 weeks in 31%; and
8 weeks in another 35%. At 12 months, both GH and IGF-I
levels were controlled in 54%. Mean tumor volume
decreased from 1405 mm
3 at baseline to 960 mm
3 at
6 months, and 799 mm
3 at 12 months (P\0.0001).
Tumor shrinkage C25% was experienced by 77% patients
during the 12-month treatment period. Symptoms (hyper-
hidrosis, paresthesia, and extremity arthralgias) were
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0.0001, P = 0.018 and P = 0.004, respectively) [65].
Grading of evidence
After reviewing the evidence available on this subject, 77%
of the Summit panel indicated that they thought the evi-
dence presented was either Category II or III. Eleven
percent thought that the evidence was at Category I and
another 11% indicated that there was not sufﬁcient evi-
dence to form an opinion (Table 2).
Level of support
In agreement with the Summit panel, only a small per-
centage of the survey participants completely accepted that
the dosing interval of an somatostatin analog can be
extended beyond once every 4 weeks without compro-
mising disease control in patients with acromegaly based
on available data in the literature. However, the majority of
both the survey respondents and Summit members indi-
cated that they accepted the statement with some (50 and
56%, respectively) or major (22% for both groups) reser-
vations. 24% of the surveyed practitioners rejected the
statement while only 11% of the Summit participants did
so (Fig. 2).
Discussion
There is clear evidence that somatostatin analogs are
consistently effective in suppressing mean GH and IGF-I
levels in patients with acromegaly and that in selected
patients, these agents can be extended beyond the 4-week
recommended dosing interval without compromising GH
or IGF-I levels or clinical response. In the subset of
responders, the beneﬁt of extended dosing demonstrated
both improved cost outcomes and greater acceptance by
patients. However, the evidence available to routinely
recommend extended dosing is incomplete.
Future direction
What is unknown is whether there are speciﬁc character-
istics that might predict a given patient’s likelihood of
responding to an extended dosing strategy. Future research
should address variables that may assist clinicians in pre-
dicting those patients most likely to beneﬁt from extended
dosing. Studies should also include larger samples and
randomized designs. Moreover, the inclusion of patient
symptomatology, QOL, and satisfaction outcomes is
essential in providing clinicians with comprehensive
information on which to base fully informed decisions in
patients with acromegaly. Finally, economic analyses
would also be of value.
Statement 6: a monthly injection of the depot form of
lanreotide or octreotide results in consistent control of
hormone levels and symptoms in patients with carcinoid
syndrome
Rationale and deﬁnition of statement
Completely effective treatment of carcinoid tumors
remains somewhat elusive. It is therefore appropriate to
carefully examine this broader topic as we investigate
evidence on the statement above. The statement initiates
several points of interest—the use of somatostatin analogs,
the level of both symptom and hormonal control, as well as
the consistency of this control—requiring some review.
Evaluation of the effects of any treatment to control
symptoms should at least include the major symptom
complex and, if possible, those less frequently recognized.
The symptom complex of carcinoid tumors includes
ﬂushing in 94%; diarrhea in 78%; cardiac-related compli-
cations in 37%; abdominal cramps in 51%; telangiectasia
in 25%; bronchoconstriction, edema, and cyanosis in 17–
18%; and arthritis, proximal myopathy, and pigmentation
in about 7% [66]. A recent retrospective analysis of 392
patients also found hypertension in 45.9% and diabetes in
9.7% of patients.
Serotonin and its excretory products are thought to be
the predominant biochemical markers of carcinoid syn-
drome, but they are notoriously weak means of detecting
and monitoring foregut and hindgut carcinoids. Chro-
mogranin (CgA) is possibly the best marker, but levels may
not correspond to symptom control. Furthermore, false
elevations are known to occur in people with severe
hypertension or renal insufﬁciency and those using proton
pump inhibitors [66–68].
Pancreastatin and neurokinin A are two emerging bio-
markers that reﬂect patient prognosis. Both have been
found to be independent prognostic indicators and strongly
associated with outcome [69–71].
Pancreastatinisapost-translationalprocessingproductof
CgA and is known to correlate with the number of liver
metastases. It has been found to be an independent indicator
(P\0.001) of poor outcome when pretreatment plasma
concentration was[500 pmol/l in patients with NETs on
multivariate, but not univariate analysis [70]. Paradoxically
increasing pancreastatin levels during somatostatin analog
therapywereobservedinsomepatientsandwerefoundtobe
associated with poorer survival on both univariate and multi-
variate analyses (both P\0.001) [70]. In another study, pan-
creastatin[5000 pg/ml pretreatment was associated with
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went hepatic artery chemoembolization and also correlated
with decreased survival (relative risk [RR] 2.6 [95% CI,
1.3–5.0]) [69].
A perfect evaluation of symptom and biochemical
control would embrace all of these. Unfortunately, regard-
less of monitoring techniques, there has been a lack of
change in long-term outcomes (including survival) from
1973–2002 per a report from Modlin et al., despite the
introduction of somatostatin analogs during that time [72].
In light of these observations, the focus of this report is to
examine evidence on the ability of somatostatin analogs to
control symptoms and biochemistries when given as short-
acting or long-acting depot analogs.
Literature search
A PubMed literature search was carried out in October
2008. Search terms used and the number of articles found
(total = 1956) are as follows:
Lanreotide (542);
Lanreotide AND ATG (6);
Octreotide (6370);
Octreotide LAR (265);
Somatostatin analogue (1324);
Long acting somatostatin analogue (3);
Lanreotide AND octreotide LAR (62);
Lanreotide ATG AND octreotide LAR (4);
Lanreotide AND octreotide LAR AND carcinoid (10);
Somatostatin analogue AND carcinoid (152);
Somatostatin analogue AND neuroendocrine tumor
(316);
Long acting somatostatin analogue AND carcinoid (1);
Long acting somatostatin analogue AND neuroendocrine
tumor (1); and,
Relevant to statement (6).
A thorough examination yielded only 5 articles both
valuable and insightful.
Evidence
Efﬁcacy of octreotide LAR was demonstrated in a retro-
spective analysis of 392 patients with carcinoid tumors
treated C4 months in unpublished data by Anthony and
Vinik. The 255 patients with diarrhea at baseline decreased
to 93 at 3 months and 47 at 12 months. Flushing was found
in 134 patients, decreasing to 52 at 3 months and 29 at
12 months. Heart disease and bronchoconstriction were
found in 20 and 21 patients respectively; at 3 months they
had decreased to 4, and at 12 months to 2, in both condi-
tions. Of particular note was the increasing improvement
observed between 3 and 12 months, although as many as
40–60% of patients had persistent symptoms. However, just
as in Modlin’s report, there was no real change in the course
of the tumors. Comorbidities such as hyperglycemia
(8.7%), cholelithiasis (6.4%), cholecystitis (2.8%), steator-
rhea (2.3%), and hypoglycemia (1.5%) were observed.
Unfortunately, the study did not include data on rates of
escape from symptom control, use of rescue medication,
or the control of biochemical markers as measures of
responsiveness.
A prospective multicenter study of 93 patients with pre-
existing control on octreotide subcutaneous (SC), was one of
the earliest papers on the efﬁcacy of octreotide LAR in car-
cinoid syndrome. After a washout period, octreotide LAR
efﬁcacy was compared with that of octreotide SC. Octreotide
SC produced complete or partial success in 58.3% patients
whereas the response to octreotide LAR was somewhat dose-
dependent (66.7% with 10 mg; 71.4% with 20 mg; and
61.9%with30 mg),althoughrescuemedicationwasrequired
in 40–60% cases [73].This has raised a question regarding
bioavailability of octreotide in the LAR preparation.
Woltering et al., in a retrospective chart review [74],
report that plasma octreotide levels after 30, 60, 120 mg/
month octreotide LAR fell with time and as a result, might
not have been reaching receptor saturation levels. While
this may partially account for the relative lack of efﬁcacy
of octreotide LAR in controlling symptoms, there are
other possible explanations. Any ‘‘position statement’’ on
symptom control warrants cautious interpretation.
A pharmacokinetic comparison showed that lanreotide
depot reaches maximum plasma concentration sooner
(mean 1.1 [range 0.25–8 days] and 2.4 days [range 0.13–
18 days], depending on dose) compared with approxi-
mately 2 weeks (mean 12.6 [range 0.02–28 days] and
22 days [range 12–34 days]) with octreotide LAR. These
differences demonstrate a potential need for using a short-
acting analog to control symptoms in the ﬁrst 2 weeks of
initiating octreotide LAR therapy, which was not evident
with lanreotide depot [75].
In the ﬁrst report on efﬁcacy of lanreotide, [76] which
was a prospective, open-label, multicenter trial, 39 patients
with nonresectable carcinoid syndrome were given lanre-
otide SR 30 mg IM every 14 days. There was a decrease in
the number of ﬂushing and diarrhea episodes after 7 and 15
days of treatment. After 7 days, complete resolution of
ﬂushing was seen in 45% and diarrhea in 17% of patients.
By 30 days, complete resolution was seen in 39 and 30% of
patients, respectively. There was a [50% decrease in 5
HIAA (hydroxyindolacetic acid) urinary concentrations in
35% of patients; no change in 50%; and an increase in 15%
within 7 days. By 30 days, these ﬁgures were 18, 57, and
25%, respectively, again emphasizing that long-acting
analogs are not impressive when it comes to controlling
major symptoms of carcinoid tumors.
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tomatic carcinoid syndrome patients compared octreotide
200–300 lg SC 2–3 x/day with lanreotide 30 mg IM every
10 days as 30-day cross-over treatment periods. Lanreotide
and octreotide were equally efﬁcacious in symptom con-
trol: ﬂushing 54 vs. 68% (disappearance or improvement);
diarrhea 45 vs. 50%; and abdominal cramps 14 vs. 29%,
respectively. There was similar reduction in tumor mark-
ers, but lanreotide SR was better tolerated than octreotide
SC due to the difference in injections. Patients preferred
lanreotide SR (68%) to octreotide SC (32%) (P = 0.03)
[77].
To prospectively assess efﬁcacy and tolerability of
lanreotide SR in previously untreated and octreotide LAR
treated patients, Ricci et al. examined 25 patients with
advanced metastatic NETs, measuring 5-hydroxyindole
acetic acid (5-HIAA), plasma CgA, serotonin, calcitonin,
and gastrin. Lanreotide SR (30 mg every 14 days [median
duration 10 months]) showed signiﬁcant efﬁcacy in terms
of objective RR and biochemical and symptom control
among both pretreated and untreated patients. Despite
lanreotide SR treatment, disease progressed in 54% of
patients, as did biochemical control in 47.5% and symp-
toms in 30%. They were stabilized in only 40, 10, and 5%,
respectively [78].
Ricci et al. examined the efﬁcacy of octreotide LAR
(20 mg IM every 4 weeks) in 15 patients with metastatic
NET with disease progression after lanreotide SR (30 mg
every 14 days) induced partial response (PR) or stable
disease (SD). Complete responses were observed in 33 and
67% of patients based on biochemical and symptomatic
criteria. Partial responses for tumor growth, biochemistry,
and symptom control were noted in 7, 8, and 8% of
patients, respectively. Stable disease was achieved in 40,
33, and 25%, respectively. Progression occurred in 53 and
26% of patients as deﬁned by objective and biochemical
measures [79].
Finally, Bajetta et al. carried out an open, prospective,
randomized 18-week trial in 60 patients with carcinoid
tumors. Patients were given either lanreotide depot 120 mg
every 6 weeks or lanreotide SR 60 mg every 3 weeks to
compare equivalence and measured symptoms, biochem-
istry, and QOL. Lanreotide depot was as effective as lan-
reotide SR in controlling NET symptoms, tumor, and QOL
[80]. Quality of life was evaluated using the European
Organization for Research and Treatment cancer QOL
(EORTC QLQ-C30) questionnaire, which has symptom,
function, and global health scales. No treatment-related
differences were found in any of these domains. Somewhat
disappointingly, no effects on these domains were found
when comparing entry scores and last observations evalu-
ated 4 to 8 weeks after commencing treatment.
Contrasting with these somewhat disappointing results
on tumor growth and hormone response is the recent report
on a prospective multicenter study of 15 patients with
gastric carcinoid tumors type 1 (GCA1). Here, 14 patients
were treated with octreotide LAR and 1 patient with lan-
reotide depot following excision of the ‘‘dominant’’ lesion
during the ﬁrst gastroscopy. In all patients, size and number
of tumors decreased after 6 months of treatment
(P\0.05). Serum gastrin levels decreased from mean
898 ± 418 mU/l to 304 ± 278 mU/l (normal range 40–
108 mU/l; P\0.005). Serum CgA, evaluated in 5 patients,
decreased from 370 ± 183 ng/ml to 148 ± 69.3 ng/ml
(mean ± SD; normal range 19.4–98.1 ng/ml, P\0.005)
[81]. Thus, somatostatin analogs may be an effective
medical therapy in gastric carcinoids, reducing tumor load,
decreasing gastrin levels, and exerting an antiproliferation
effect on enterochromafﬁn-like (ECL) cells.
The apparent effectiveness in GCAI gastric carcinoids
addresses the issue of the selectivity of somatostatin ana-
logs for SST receptors on different tumors. Octreotide and
lanreotide bind most strongly to somatostatin receptor-2
(SSTR2), to a lesser extent SSTR3 and SSTR5, and vir-
tually not at all to SSTR1 and SSTR4 [82]. Thus,
somatostatin analogs with other receptor speciﬁcities may
have different effects on selective types of NETs.
Grading of evidence
Eighty-nine percent of the Summit participants considered
the evidence to be Category II. Only 11 percent considered
the strongest evidence available was that obtained from
case series, reports, or ﬂawed clinical trials (Category III)
(Table 2).
Level of support
Very similar percentages of survey respondents and Sum-
mit participants accepted this statement (89 and 88%,
respectively). In both groups, there were a considerable
number who had some reservations as well as those with
major reservations. Eleven percent of each group rejected
the statement, also mostly with reservation. See Fig. 2 for
more detail.
Discussion
Reservation in the acceptance of this statement, similar
among both surveyed practitioners and Summit partici-
pants, might be related to the presence of multiple com-
ponents of the statement itself. The level of evidence varied
in regard to each of these components (monthly dosing,
hormone and symptom control, and consistency of control).
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somatostatin analogs are capable of controlling the symp-
tom complex of NETs, but lesser acceptance that they are
able to control tumor growth or biochemical abnormalities.
In this regard, the quality of evidence is only Category II
although what data is available does suggest that they are
relatively ineffective; one trial using a poor tool suggests
that they may not enhance QOL. Of note, data from a
randomized, double blind, placebo-controlled study of
85 patients with gastroenteropancreatic neuroendocrine
tumors (the PROMID Study Group) [83] was presented
subsequent to the Summit. The octreotide LAR group
experienced signiﬁcantly increased time to progression
compared with the placebo group (14.3 vs. 6 months,
P = 0.000072). At 6 months, stable disease was noted
among 67 and 37%, respectively [83].
There is overwhelming evidence based on clinical trials,
case reports, and case control studies indicating that
somatostatin analogs are safe and have the ability to control
certain symptoms of carcinoid tumors. Nonetheless, the
trials have been relatively small and of short duration.
Numerous small studies make it clear that octreotide LAR
can control symptoms among approximately two-thirds of
subjects, but that escape occurs at varying intervals of time
for ﬂushing and diarrhea, requiring the use of short-acting
analogs that seem to have greater efﬁcacy. The reason for
this discrepancy is not clear and may relate to a variety of
reasons such as bioavailability, pharmacokinetics and
dynamics, or even changes in the bioavailability of dif-
ferent batches of the drugs.
A paradox is seen regarding response to lanreotide in
patients failing octreotide and vice versa. Although the
binding to the SSTR of each agent appears to be the same
in vitro, these peptides differ sufﬁciently so that their
action in vivo appears to defy the SSTR binding rules.
Accruing evidence reveals that loss of bioavailability of
octreotide LAR needs to be monitored using blood levels.
Escape from control may not reﬂect loss of efﬁcacy of the
drug, tachyphylaxis, appearance of antibodies, or mutation
in the cell type of the tumor, but simply a state of
decreasing bioavailability. Furthermore, the vast symptom
complex and its potential multitude of mechanisms, many
of which are not susceptible to inhibition by SST alone,
may require combinations with agents targeting the alter-
nate pathogenetic mechanisms.
Future direction
Better trials are needed to compare the analogs. Head-to-
head, randomized comparisons are needed with the dif-
ferent long-acting analogs outlining a clear deﬁnition of the
patient population. A placebo-controlled trial, using dif-
ferent somatostatin analogs with different speciﬁcities for
SSTR and carried out among well-characterized patients
with NETs for a sufﬁcient period of time, should be aimed
at establishing an appropriate dose range that achieves
blood levels optimally saturating SSTRs.
In this day of evidenced-based medicine, orphan dis-
eases such as NETs may have great difﬁculty fulﬁlling the
requirements of a double-blind, randomized, placebo-con-
trolled trial in a sufﬁciently large population of subjects.
Since there are no centers with a sufﬁciently large popu-
lation to carry out these needed studies, it behooves NET-
oriented researchers to pool resources. In this way, larger
scale multicenter studies may eventually yield rewarding
results. Without this cooperative effort, our expectation can
probably never exceed a Category II recommendation or
acceptance.
Determining the reasons for differences in response may
require evaluation of pharmacokinetics and pharmacody-
namics of different long-acting analogs compared with
their short-lived counterparts. In addition, the presence of
different receptor subtypes and their speciﬁcity in different
NET tumor types might dictate a need for tailoring somato-
statin analogs to the tumor.
The disappointing results with somatostatin analogs on
tumor growth over the last 3 decades should spur investi-
gators into seeking new and alternate approaches to con-
trolling tumor growth, such as tyrosine kinase inhibitors
[84], mammalian target of rapamycin (mTOR) inhibitors
[85], or combination therapies that include interferons [86].
Additionally, many studies have focused upon diarrhea
and ﬂushing, but ignored the remainder of the vast symp-
tom complex of NETs. Indeed, none have looked into the
effects of cardiovascular disease, bronchospasm, or bone
metastases. Since these are slow-growing tumors with a
relatively long period of stable growth and tumor mass not
readily amenable to treatment, QOL measures are needed
to address all symptoms that may beset the patient with an
NET [87].
Conclusions
An endocrinology panel was convened to provide evi-
dence-based recommendations regarding the use of GH
and IGF-I measurements in acromegaly and the use of
somatostatin analogs in the management of patients with
acromegaly or NETs. Overall, evidence supported the use
of IGF-I measurements to assess disease control in acro-
megaly and the need for standardized assays and large
normative data bases was emphasized. Summit panel
opinion, as compared to surveyed community-based prac-
titioners, is detailed in Fig. 2.
Panelists felt that data regarding either random GH
levels or GH day curves in assessing disease control and
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the role of GH suppression as a therapeutic endpoint in the
care of patients with known acromegaly was not substan-
tiated. The change in assay methodology over the years and
the increased sensitivity of newer GH assays compared to
older assays was noted. The recommended goal of therapy
for patients with acromegaly is GH\1 lg/l because
a\2.5 lg/l (as assessed by older assays in past studies)
correlated with normalization of the high mortality rate
associated with acromegaly. The Summit panel concluded
that both IGF-I and GH levels could be used to evaluate the
activity of acromegaly, particularly when values were
discrepant. However, GH cutoff values should be inter-
preted and reanalyzed according to patient’s gender, age,
BMI, gonadal status, and speciﬁc assay used.
Regarding the use of somatostatin analogs in man-
agement of acromegaly, consideration was given to the
statements that patients could be controlled with pro-
longed dosing intervals. Based on the small number of
studies available, none controlled, the Summit panel felt
that although some patients could be controlled with
prolonged dosing intervals, there was insufﬁcient data to
recommend this and no data available as to predictors of
this response.
As for the use of somatostatin analogs prior to surgery
in patients with acromegaly, the Summit panel concluded
that the administration of somatostatin analogs prior to
transsphenoidal surgery improves surgical outcome and
disease morbidity associated with acromegaly. However,
these data applied to macroadenomas and there was no
evidence supporting its use in microadenomas unless
metabolic or anesthesia risks associated with soft tissue
swelling were of immediate concern. Longer term ran-
domized studies were needed to assess the overall beneﬁt
of this strategy.
Finally, the Summit panel considered the use of
somatostatin analogs in the management of NETs. There
was a consensus that this therapy can control a number of
symptoms due to carcinoid tumors, although studies have
been of short duration. However, in contrast to the data in
acromegaly, escape may occur, requiring the use of short-
acting analogs. This escape may reﬂect tachyphylaxis,
development of antibodies, changing cell populations in the
tumor, and/or decreasing bioavailability. In addition,
although somatostatin analogs can control disease symp-
toms, hormone hypersecretion, and tumor growth in many
patients with acromegaly, these analogs are not effective in
treating tumor burden in NETs.
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